Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire

Abstract Background Neoadjuvant immunotherapy utilizing novel combinations has the potential to transform the standard of care for locally/regionally advanced melanoma. We hypothesized that neoadjuvant ipilimumab in combination with high dose IFNα2b (HDI) is safe and associated with durable patholog...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ahmad Tarhini, Yan Lin, Huang Lin, Zahra Rahman, Priyanka Vallabhaneni, Prateek Mendiratta, James F. Pingpank, Matthew P. Holtzman, Erik C. Yusko, Julie A. Rytlewski, Uma N. M. Rao, Robert L. Ferris, John M. Kirkwood
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 2018-10-01
coleção:	Journal for ImmunoTherapy of Cancer
Assuntos:	Immunotherapy Ipilimumab Anti-CTLA-4 Interferon Melanoma
Acesso em linha:	http://link.springer.com/article/10.1186/s40425-018-0428-5
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!